The most common reason TRT goes sideways is not the dose. It's the monitoring -- or the lack of it. Men get a single post-baseline draw at month three, see a number they like, and never test again. Then a year later they walk into urgent care with a hematocrit of 56 and a blood pressure they can't explain.
Bloodwork is not optional on testosterone therapy. It is the entire feedback loop. The right schedule catches problems while they are still small adjustments and tells you when your protocol is actually working.
Key Takeaways
- Baseline labs before starting TRT establish the reference point you will track against for years
- The first year requires 4-5 lab draws -- baseline, 6-8 weeks, 3 months, 6 months, 12 months
- Once stable, labs every 6-12 months are sufficient unless something changes
- Always draw at trough (just before your next injection), not at peak, for honest data
- The essential panel is total T, free T or SHBG, estradiol, and CBC -- everything else is situational
- Recheck 6-8 weeks after every protocol change (dose, frequency, route)
Why Timing the Draw Matters More Than Any Other Variable
If you remember one thing from this guide, remember this: draw at trough.
Trough means the lowest point in your dosing cycle, which is the morning before your next injection. For a man on once-weekly testosterone cypionate dosing on Sunday morning, the trough draw is Sunday morning, immediately before the next dose. For twice-weekly Monday/Thursday, trough is Monday morning before the Monday dose, or Thursday morning before the Thursday dose.
Why this is non-negotiable:
Peak draws lie. Testosterone cypionate produces a peak around 24-48 hours after injection. A man on 140mg weekly might peak at 1,400 ng/dL but trough at 500. If you draw 24 hours post-injection, the lab tells you he's well-medicated. He isn't -- he is hypogonadal for half his week.
Trough is what your tissues see most of the time. The whole point of TRT is to deliver consistent androgen exposure. The trough number tells you whether your protocol is doing that.
Dose decisions made on peak data are usually wrong. A trough of 450 with a peak of 1,200 means your peak-to-trough ratio is too wide -- the answer is more frequent injections, not a lower dose. A peak draw would show the 1,200 and trigger a reflexive dose cut that drops your trough into hypogonadal range.
For gels and creams, draw 2-6 hours after application (per FDA label). For pellets, the timing matters less but draw at the midpoint between insertions for steady-state values. For oral testosterone, follow the specific product label -- typically pre-dose or at a defined post-dose interval.
A useful pharmacokinetic review by Pastuszak and colleagues laid out the peak-to-trough variability across formulations -- weekly intramuscular injections produce the widest swings, daily transdermals the narrowest, and subcutaneous injections sit between the two. Your sampling time has to match what the formulation actually does in serum.
The Baseline Panel: What to Run Before Starting TRT
Baseline labs do two jobs. First, they confirm the diagnosis -- you cannot prescribe testosterone therapy on symptoms alone. Second, they establish the reference point you will compare every future draw against. Skipping baseline is one of the most common mistakes in low-quality online clinics.
The Endocrine Society 2018 guideline (Bhasin et al.) and the AUA 2018 guideline (Mulhall et al.) both require two morning total testosterone measurements below 300 ng/dL on separate days before initiating therapy.
Required Baseline Labs
| Lab |
Why |
| Total testosterone (morning, fasted not required) |
Confirm hypogonadism. Two values below 300 ng/dL on separate mornings |
| Free testosterone (or SHBG to calculate it) |
Catches normal-total/low-free presentations |
| LH and FSH |
Distinguishes primary vs secondary hypogonadism. Critical for fertility-preserving decisions |
| Estradiol (sensitive assay) |
Baseline for tracking aromatization response |
| SHBG |
Drives free testosterone interpretation. Often abnormal in men with metabolic disease |
| Prolactin |
Rules out pituitary cause of low T |
| CBC with differential |
Baseline hematocrit. Do not start TRT if baseline hematocrit is above 50% |
| Comprehensive metabolic panel |
Liver, kidney function for prescribing safety |
| Lipid panel |
TRT alters lipid profile in some men. Need a starting point |
| PSA (men 40+) |
Required by AUA/Endocrine Society before TRT in men over 40 |
| HbA1c or fasting glucose |
Many low-T men have undiagnosed prediabetes that affects clinical interpretation |
Optional Add-Ons That Sometimes Pay Off
- Ferritin and iron studies -- low ferritin will cause fatigue that mimics low T and complicates phlebotomy decisions later
- TSH and free T4 -- thyroid dysfunction is common in men with low T and produces overlapping symptoms
- Vitamin D 25-OH -- deficiency is rampant and depresses testosterone
- IGF-1 -- baseline if growth hormone or peptide therapy is on the table
- DHEA-S -- only useful if adrenal pathology is suspected
Skip the expensive proprietary panels (the ones with 50+ markers and a four-figure price tag) unless your clinic insists. They generate noise without changing decisions for most men.
For more on what these markers mean, see our guide on how to read testosterone labs and total vs free testosterone.
The First Year Schedule
The first year of TRT is when nearly all protocol adjustments happen. Hematocrit climbs, estradiol shifts, your body recalibrates SHBG, and your symptoms either improve or they don't. The schedule below is what most evidence-based clinics actually run, aligned with Endocrine Society and AUA guidelines.
Recommended First-Year Schedule
| Timepoint |
What to Run |
Why |
| Baseline (pre-TRT) |
Full baseline panel above |
Diagnose, establish reference |
| 6-8 weeks |
Total T, free T, estradiol, CBC |
First steady-state check. Dose-adjust here, not earlier |
| 3 months |
Total T, free T, estradiol, CBC, SHBG |
Confirm dose. Hematocrit response becoming visible |
| 6 months |
Total T, free T, estradiol, CBC, lipid panel, PSA (if 40+) |
Mid-year comprehensive. Hematocrit often peaks here |
| 12 months |
Full baseline panel repeat |
Annual comprehensive. Sets stage for ongoing surveillance |
Why 6-8 Weeks Is the Magic Number for the First Recheck
Testosterone cypionate has a half-life of approximately 8 days. Steady state requires 4-5 half-lives, which is 32-40 days, or about 5-6 weeks. Drawing labs earlier than that shows a moving target -- the number is climbing, not stable.
Six to eight weeks is the sweet spot: serum levels have stabilized, hematocrit has had time to start responding, and you have enough data to make an evidence-based dose decision.
If you change your protocol at any point in the first year (dose, frequency, route, or adding HCG), the 6-8 week clock restarts. Recheck before making another change.
What Counts as a "Successful" Lab Profile
There is no single right number. The targets below are what most experienced TRT clinicians shoot for in symptomatic men with reasonable side effect tolerance:
- Total testosterone (trough): 600-900 ng/dL for most men. Higher (900-1,100) sometimes acceptable with good free T and managed hematocrit
- Free testosterone (trough): 15-25 ng/dL (or upper third of the assay's reference range)
- Estradiol (sensitive assay): 20-40 pg/mL. Above 50 with symptoms warrants management. Below 15 is a problem
- Hematocrit: Below 52%. Above 54% requires intervention. See our hematocrit management guide for the full playbook
- SHBG: 20-50 nmol/L. Outside that range your free T calculation needs attention. Low SHBG men need special protocols
- PSA: Stable. A rise of more than 1.4 ng/mL above baseline warrants urological referral
If your numbers are in range but you still feel bad, the answer is rarely "more testosterone." It is usually estradiol, SHBG, sleep, or another hormonal axis.
After Year One: The Maintenance Schedule
Once your protocol is dialed in and your year-one labs look stable, the monitoring burden drops significantly. The European Association of Urology and the Endocrine Society both endorse annual monitoring for stable patients, with more frequent checks for men with risk factors.
Long-Term Maintenance Schedule
| Status |
Lab Frequency |
What to Run |
| Stable, no risk factors |
Every 12 months |
Total T, free T, estradiol, CBC, PSA (40+), lipid panel |
| Hematocrit history above 52% |
Every 6 months |
Above plus extra CBC at 9 months |
| PSA history elevated or family history |
Every 6 months |
Above plus repeat PSA |
| Recent protocol change |
6-8 weeks post-change |
Total T, free T, estradiol, CBC |
| New symptoms (fatigue, mood, libido) |
As soon as possible |
Full panel plus situational add-ons |
When to Break the Schedule and Test Sooner
A scheduled lab is a snapshot. Don't wait for it if any of the following happen:
- New persistent headaches, facial flushing, vision changes (suggests high hematocrit)
- Sudden mood changes, water retention, breast tenderness (suggests estradiol shift)
- Loss of morning erections or libido after they had returned (suggests dose, free T, or estradiol problem)
- Unexplained fatigue despite a previously dialed-in protocol
- Significant weight change (>10 lbs in either direction will shift SHBG and free T calculations)
- New medication started (especially anything that affects liver enzymes, GLP-1 agonists, finasteride)
A targeted draw triggered by a real symptom is more valuable than a scheduled draw at month 12.
Common Bloodwork Mistakes (And How to Avoid Them)
Even men who follow a schedule make systematic errors that produce bad data and worse decisions.
Mistake 1: Drawing at Peak Instead of Trough
Already covered, but it is by far the most common error. Some clinics quietly schedule labs at convenient times rather than at trough -- because they want a "good number" for the chart, or because the patient asked to come in mid-week. The result: every dose decision is based on inflated data.
Fix: Schedule trough draws explicitly. If you inject Sunday morning, request a Sunday-morning lab time slot the following week.
Mistake 2: Skipping the CBC
Total testosterone is sexy. Hematocrit is the one that puts you in the hospital. Yet some men ask for "just a testosterone level" to save money on lab fees and skip the CBC for a year or two.
Fix: Hematocrit is non-negotiable. Run a CBC every time you check testosterone in years one and two. After that, every six months at minimum.
Mistake 3: Using Non-Sensitive Estradiol Assays
Standard estradiol assays are designed for women's hormone ranges and are inaccurate at the lower end of the spectrum where men live. A "high" estradiol on a non-sensitive assay can be a normal value on a sensitive (LC-MS) assay.
Fix: Always order an estradiol sensitive (or "estradiol, ultrasensitive") test. The assay code matters. If your lab does not offer it, find one that does.
Mistake 4: Drawing Labs Too Early After a Change
Switched from 140mg weekly to 70mg twice weekly? Don't draw at three weeks. The new steady state takes another 5-6 weeks to establish. Drawing too early shows a transitional value that doesn't reflect where the new protocol will settle.
Fix: Wait 6-8 weeks after any protocol change before pulling labs.
Mistake 5: Treating the Number Instead of the Patient
A lab report is data. The patient is a person with symptoms, energy, libido, sleep quality, and body composition. Sometimes a man feels great with a "low" estradiol or a "high" total. Sometimes a man feels terrible with picture-perfect numbers.
Fix: Track both. Numbers + symptoms together drive decisions. Numbers alone do not.
Mistake 6: Ignoring Trends in Favor of Single Values
A single lab is a snapshot. The trend is the truth. A hematocrit that goes from 47 to 50 to 52 in three checks is heading somewhere. A one-time 52 with prior values of 48 might be a hydration issue or measurement noise.
Fix: Keep your last 3-4 labs accessible (or use a clinic that does). Track changes, not absolutes.
Special Situations Requiring Modified Schedules
A handful of clinical scenarios require a different cadence.
Men with Cardiovascular Risk Factors
The TRAVERSE trial demonstrated that TRT in men with cardiovascular disease or high CV risk did not increase major adverse cardiovascular events compared to placebo. But it did show modest increases in atrial fibrillation and acute kidney injury. Men with established cardiovascular disease should run additional monitoring -- blood pressure at every visit, an annual ECG, and lipid panels every 6 months rather than annually. See our TRAVERSE summary for details.
Men on TRT Plus HCG
Adding HCG complicates the picture. HCG can elevate estradiol significantly and shift SHBG. Men on combined TRT + HCG protocols typically need labs every 3 months for the first 6 months of the combination, with sensitive estradiol and SHBG every time. See our HCG fertility protocol guide.
Men on TRT Plus Aromatase Inhibitors
Aromatase inhibitors can crash estradiol and damage bone density. Men on AIs need estradiol checks every 6-8 weeks until stable, then every 3-4 months ongoing. A DEXA scan at baseline and again at 18-24 months is a reasonable add. See aromatase inhibitors on TRT for the cautions.
Men with Low SHBG
Low SHBG drives both faster testosterone clearance and inflated free T relative to total T. These men need more frequent labs -- every 6-8 weeks until a daily or every-other-day microdosing protocol stabilizes them, then every 3 months. See low SHBG TRT protocol.
Men Above 65
Older men have higher baseline cardiovascular and prostate risk. A 6-month rather than 12-month maintenance cadence makes sense, with PSA every 6 months and a urology check-in annually.
How to Read the Results Without Panicking
A lab outside the reference range is not automatically a crisis. Some perspective:
- Reference ranges are population averages. They include men at every age and disease state. Your "out of range" might be perfectly fine for your context.
- Lab error is real. Single values that look weird should be repeated before action. Especially for hematocrit (hydration affects it) and estradiol (assay variability).
- Trends matter more than single readings. A stable 51% hematocrit is different from a hematocrit that was 47 three months ago.
- Symptoms must be in the equation. A "concerning" lab in an asymptomatic patient deserves a recheck, not a panicked dose change.
Our how to read testosterone labs walks through interpretation marker by marker.
Cost Considerations
A full first-year monitoring protocol -- baseline plus four follow-ups with comprehensive panels -- runs $400-$1,200 out of pocket if your insurance does not cover it. Many TRT clinics include 2-4 lab draws per year in their monthly fee. Standalone direct-to-consumer lab services (Quest, LabCorp through online platforms) typically charge $80-$150 for a focused TRT panel.
Insurance coverage of TRT labs is variable. CBC, lipids, and PSA are generally covered. Estradiol sensitive and free testosterone are sometimes pushed back as "experimental." If your clinic does not handle the insurance side, expect to pay cash and submit for reimbursement yourself.
For comparison of clinic models and what's typically included, see TRT pricing what to pay and TRT with insurance vs without.
The Bottom Line
A working TRT protocol depends on a working monitoring protocol. Baseline labs confirm the diagnosis. Six-to-eight-week labs catch the initial response. Three- and six-month labs catch the hematocrit and estradiol drift. Year-one labs lock in your stable protocol. After that, every 6-12 months is enough unless something changes.
The two errors that cause most TRT problems are skipping monitoring entirely and drawing at peak instead of trough. Both are easy to fix. Both, when fixed, prevent the cascade of bad decisions that turn TRT from a quality-of-life intervention into a slow-motion side effect problem.
If your current clinic has not laid out a monitoring schedule like the one above -- or worse, if they have not pulled labs since you started -- that is a red flag. See TRT clinic red flags for the full list, and our independently scored TRT clinic reviews for providers with structured monitoring built into the protocol.
You are paying for a feedback loop. Make sure you are getting one.
References
-
Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PMID: 29562364
-
Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423-432. PMID: 29601923
-
Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389(2):107-117. PMID: 37326322
-
Pastuszak AW, Gittelman M, Tursi JP, et al. Pharmacokinetics of testosterone therapies in relation to diurnal variation of serum testosterone levels as men age. Andrology. 2022;10(2):209-222. PMID: 34510812
-
Permpongkosol S, Khupulsup K, Leelaphiwat S, et al. Comparison of Outcomes for Hypogonadal Men Treated with Intramuscular Testosterone Cypionate versus Subcutaneous Testosterone Enanthate. J Urol. 2022;207(3):677-685. PMID: 34694927
-
Corona G, Goulis DG, Huhtaniemi I, et al. European Academy of Andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males. Andrology. 2020;8(5):970-987. PMID: 32026626
-
Bachman E, Travison TG, Basaria S, et al. Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point. J Gerontol A Biol Sci Med Sci. 2014;69(6):725-735. PMID: 24158761
-
Ohlander SJ, Varghese B, Pastuszak AW. Erythrocytosis and Polycythemia Secondary to Testosterone Replacement Therapy in the Aging Male. Sex Med Rev. 2017;5(2):195-206. PMID: 27784544